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Identity 
Other names: P300; E1A binding protein p300 




9046 bp mRNA; coding sequence: 7244 bp. 
Protein 
Description 
2414 amino acids; 264 kDa. 
Expression 
Widely expressed ; also expressed in the whole 
embryo; possesses from N term to C term: a nuclear 
localization signal, a poly-serine, a bromodomain, a 





p300 and CBP are highly related proteins implicated in 
transcriptional responses to various extracellular and 
intracellular signals with chromatin remodeling; they 
are non-DNA-binding transcriptional coactivators; they 
interact with transcriptional activators as well as 
repressors; p300 and CBP are involved in most cellular 
programs, including growth, terminal differentiation, 
and P53-mediated apoptosis (with MDM2 interaction) 
processes; p300 and CBP appear to have distinct  
 
 
functions during differentiation; there is embryonic  
lethality of mice nullizygous for p300 (with defects in 
neurulation and heart development), and as well of 
mice double heterozygous for p300 and CBP, 








Therapy related acute non lymphocytic leukemia. 
Hybrid/Mutated gene 
5 MLL-3 P300. 
Abnormal protein 
N-term MLL fused to C-term P300. 
Oncogenesis 
Likely to be driven by the MLL part. 
Gastric and colorectal carcinomas 
Oncogenesis 
Mutations in both alleles. 
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